Stocks:
5,782
ETFs:
2,400
Exchanges:
11
Market Cap:
$53.67T
24h Vol:
$12.01B
Dominance:
AAPL:5.50%
Stocklytics Platform
Instrument logo  LLY

Eli Lilly & Co

LLY
76 / 100
$591.03-0.13%-$0.82

Performance History

Placeholder
Key Stats
Open$591.46
Prev. Close$591.85
EPS5.50
Dividend$4.37
Next Earnings DateAug 8, 2023
Dividend Yield %
0.76%
Market Cap
$561.07B
PE Ratio
107.46
lowhigh
Day Range586.21
596.22
52 Week Range309.20
629.96
Ratios
P/B Ratio
50.07
Revenue
$32.07B
Operating M. %
37.28%
Earnings
$4.98B
Earnings Growth %
36.84%
EBITDA Margin %
35.28%
ROE %
46.46%
EPS5.50

Score Breakdown

76vs 52. Market Avg.

All Score (76 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

LLYMarket
Value
21
42
Quality
70
46
Ownership
97
39
Growth
96
44
Dividends
34
32

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$552.96
24H (%)3.36%
24H ($)$17.98
MARKET CAP$511.45B
PRICE$154.66
24H (%)1.67%
24H ($)$2.55
MARKET CAP$372.30B
PRICE$102.48
24H (%)1.33%
24H ($)$1.35
MARKET CAP$259.68B
PRICE$142.39
24H (%)2.80%
24H ($)$3.89
MARKET CAP$251.39B

About Eli Lilly & Co (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

ISN
-
Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. David A. Ricks
Headquarters
Indianapolis
Employees
39000
add Eli Lilly & Co to watchlist

Keep an eye on Eli Lilly & Co

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.